Journal of Clinical Investigation · 2014 · 285 citations · 13 references
Life SciencesImmunologyOncologyImmunoregulationImmunotherapyTumor ImmunologyAntigen RecognitionCancer ImmunotherapyCheckpoint Inhibitor TherapyT Cell ActivationT Cell Activation ControlT Cell BiologyAgonist AntibodiesCd4 Positive T Cell ResponsesCd4 Positive T CellsCd4 T Cell ActivationCoinhibitory ReceptorsImmune System ModulationMurine ModelsT-cell Mediated Responses
T cell activation is regulated by the interactions of surface receptors with stimulatory and inhibitory ligands. Programmed death-1 homolog (PD-1H, also called VISTA) is a member of the CD28 family of proteins and has been shown to act as a coinhibitory ligand on APCs that suppress T cell responses. Here, we determined that PD-1H functions as a coinhibitory receptor for CD4⁺ T cells. CD4⁺ T cells in mice lacking PD-1H exhibited a dramatically increased response to antigen stimulation. Furthermore, delivery of a PD-1H-specific agonist mAb directly inhibited CD4⁺ T cell activation both in vitro and in vivo, validating a coinhibitory function of PD-1H. In a murine model of acute hepatitis, administration of a PD-1H agonist mAb suppressed CD4⁺ T cell-mediated acute inflammation. PD-1H-deficient animals were highly resistant to tumor induction in a murine brain glioma model, and depletion of CD4⁺ T cells, but not CD8⁺ T cells, promoted tumor formation. Together, our findings suggest that PD-1H has potential as a target of immune modulation in the treatment of human inflammation and malignancies.
13
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text
Life Sciences, Immunology, Oncology +17
Melinda Fitzgerald, Ian P. Hayward, Anita C. Thomas et al. · 1995 · 2.6K citations